Severe eosinophilia and subsequent dermatologic immune‐related adverse event with squamous cell carcinoma antigen elevation induced by nivolumab and ipilimumab
Abstract Immune checkpoint inhibitors (ICIs) for malignant lesions are associated with immune‐related adverse events (irAEs), but reports about severe eosinophilia induced by ICIs are scarce. A 73‐year‐old man with lung squamous cell carcinoma was treated by chemotherapy (carboplatin plus paclitaxel...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-10-01
|
| Series: | Respirology Case Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/rcr2.1037 |
| _version_ | 1818017327226028032 |
|---|---|
| author | Takeshi Matsumoto Akiko Kaneko Yusuke Kusakabe Emi Nakayama Ayaka Tanaka Naoki Yamamoto Kensaku Aihara Shinpachi Yamaoka Michiaki Mishima |
| author_facet | Takeshi Matsumoto Akiko Kaneko Yusuke Kusakabe Emi Nakayama Ayaka Tanaka Naoki Yamamoto Kensaku Aihara Shinpachi Yamaoka Michiaki Mishima |
| author_sort | Takeshi Matsumoto |
| collection | DOAJ |
| description | Abstract Immune checkpoint inhibitors (ICIs) for malignant lesions are associated with immune‐related adverse events (irAEs), but reports about severe eosinophilia induced by ICIs are scarce. A 73‐year‐old man with lung squamous cell carcinoma was treated by chemotherapy (carboplatin plus paclitaxel) and ICIs (nivolumab plus ipilimumab). After two cycles of chemotherapy, the ICIs were continued. After 5 months, the eosinophilia, which had exceeded 5000/μl, increasingly deteriorated, and the only detected irAE was a grade 1 rash. Under continuation of the ICIs, although the eosinophilia decreased, a grade 3 rash and severe pruritis subsequently appeared. Squamous cell carcinoma antigen (SCCA) was steeply increased simultaneously. A complete response had been achieved, and oral prednisolone markedly improved the rash, pruritis, and eosinophilia. Clinicians should be aware that precedent severe eosinophilia and subsequent severe irAE could occur in patients treated by nivolumab and ipilimumab, and SCCA elevation could be associated with dermatologic irAE. |
| first_indexed | 2024-04-14T07:25:38Z |
| format | Article |
| id | doaj.art-9899d96e423f4c36bd32d53083fe83f7 |
| institution | Directory Open Access Journal |
| issn | 2051-3380 |
| language | English |
| last_indexed | 2024-04-14T07:25:38Z |
| publishDate | 2022-10-01 |
| publisher | Wiley |
| record_format | Article |
| series | Respirology Case Reports |
| spelling | doaj.art-9899d96e423f4c36bd32d53083fe83f72022-12-22T02:06:02ZengWileyRespirology Case Reports2051-33802022-10-011010n/an/a10.1002/rcr2.1037Severe eosinophilia and subsequent dermatologic immune‐related adverse event with squamous cell carcinoma antigen elevation induced by nivolumab and ipilimumabTakeshi Matsumoto0Akiko Kaneko1Yusuke Kusakabe2Emi Nakayama3Ayaka Tanaka4Naoki Yamamoto5Kensaku Aihara6Shinpachi Yamaoka7Michiaki Mishima8Department of Respiratory Medicine Saiseikai‐Noe Hospital Osaka JapanDepartment of Respiratory Medicine Saiseikai‐Noe Hospital Osaka JapanDepartment of Respiratory Medicine Saiseikai‐Noe Hospital Osaka JapanDepartment of Respiratory Medicine Saiseikai‐Noe Hospital Osaka JapanDepartment of Respiratory Medicine Saiseikai‐Noe Hospital Osaka JapanDepartment of Respiratory Medicine Saiseikai‐Noe Hospital Osaka JapanDepartment of Respiratory Medicine Saiseikai‐Noe Hospital Osaka JapanDepartment of Respiratory Medicine Saiseikai‐Noe Hospital Osaka JapanDepartment of Respiratory Medicine Saiseikai‐Noe Hospital Osaka JapanAbstract Immune checkpoint inhibitors (ICIs) for malignant lesions are associated with immune‐related adverse events (irAEs), but reports about severe eosinophilia induced by ICIs are scarce. A 73‐year‐old man with lung squamous cell carcinoma was treated by chemotherapy (carboplatin plus paclitaxel) and ICIs (nivolumab plus ipilimumab). After two cycles of chemotherapy, the ICIs were continued. After 5 months, the eosinophilia, which had exceeded 5000/μl, increasingly deteriorated, and the only detected irAE was a grade 1 rash. Under continuation of the ICIs, although the eosinophilia decreased, a grade 3 rash and severe pruritis subsequently appeared. Squamous cell carcinoma antigen (SCCA) was steeply increased simultaneously. A complete response had been achieved, and oral prednisolone markedly improved the rash, pruritis, and eosinophilia. Clinicians should be aware that precedent severe eosinophilia and subsequent severe irAE could occur in patients treated by nivolumab and ipilimumab, and SCCA elevation could be associated with dermatologic irAE.https://doi.org/10.1002/rcr2.1037Immune‐related adverse eventipilimumabnivolumabsevere eosinophiliasquamous cell carcinoma antigen. |
| spellingShingle | Takeshi Matsumoto Akiko Kaneko Yusuke Kusakabe Emi Nakayama Ayaka Tanaka Naoki Yamamoto Kensaku Aihara Shinpachi Yamaoka Michiaki Mishima Severe eosinophilia and subsequent dermatologic immune‐related adverse event with squamous cell carcinoma antigen elevation induced by nivolumab and ipilimumab Respirology Case Reports Immune‐related adverse event ipilimumab nivolumab severe eosinophilia squamous cell carcinoma antigen. |
| title | Severe eosinophilia and subsequent dermatologic immune‐related adverse event with squamous cell carcinoma antigen elevation induced by nivolumab and ipilimumab |
| title_full | Severe eosinophilia and subsequent dermatologic immune‐related adverse event with squamous cell carcinoma antigen elevation induced by nivolumab and ipilimumab |
| title_fullStr | Severe eosinophilia and subsequent dermatologic immune‐related adverse event with squamous cell carcinoma antigen elevation induced by nivolumab and ipilimumab |
| title_full_unstemmed | Severe eosinophilia and subsequent dermatologic immune‐related adverse event with squamous cell carcinoma antigen elevation induced by nivolumab and ipilimumab |
| title_short | Severe eosinophilia and subsequent dermatologic immune‐related adverse event with squamous cell carcinoma antigen elevation induced by nivolumab and ipilimumab |
| title_sort | severe eosinophilia and subsequent dermatologic immune related adverse event with squamous cell carcinoma antigen elevation induced by nivolumab and ipilimumab |
| topic | Immune‐related adverse event ipilimumab nivolumab severe eosinophilia squamous cell carcinoma antigen. |
| url | https://doi.org/10.1002/rcr2.1037 |
| work_keys_str_mv | AT takeshimatsumoto severeeosinophiliaandsubsequentdermatologicimmunerelatedadverseeventwithsquamouscellcarcinomaantigenelevationinducedbynivolumabandipilimumab AT akikokaneko severeeosinophiliaandsubsequentdermatologicimmunerelatedadverseeventwithsquamouscellcarcinomaantigenelevationinducedbynivolumabandipilimumab AT yusukekusakabe severeeosinophiliaandsubsequentdermatologicimmunerelatedadverseeventwithsquamouscellcarcinomaantigenelevationinducedbynivolumabandipilimumab AT eminakayama severeeosinophiliaandsubsequentdermatologicimmunerelatedadverseeventwithsquamouscellcarcinomaantigenelevationinducedbynivolumabandipilimumab AT ayakatanaka severeeosinophiliaandsubsequentdermatologicimmunerelatedadverseeventwithsquamouscellcarcinomaantigenelevationinducedbynivolumabandipilimumab AT naokiyamamoto severeeosinophiliaandsubsequentdermatologicimmunerelatedadverseeventwithsquamouscellcarcinomaantigenelevationinducedbynivolumabandipilimumab AT kensakuaihara severeeosinophiliaandsubsequentdermatologicimmunerelatedadverseeventwithsquamouscellcarcinomaantigenelevationinducedbynivolumabandipilimumab AT shinpachiyamaoka severeeosinophiliaandsubsequentdermatologicimmunerelatedadverseeventwithsquamouscellcarcinomaantigenelevationinducedbynivolumabandipilimumab AT michiakimishima severeeosinophiliaandsubsequentdermatologicimmunerelatedadverseeventwithsquamouscellcarcinomaantigenelevationinducedbynivolumabandipilimumab |